Authors

• Zaipei Guo (ORCID: https://orcid.org/0000-0001-6671-8304)
• Xiuqin Dong (ORCID: https://orcid.org/0000-0002-7335-7110)
• Weili Pan
• Songmei Geng (ORCID: https://orcid.org/0000-0001-8731-6267)
• Xing‐Hua Gao (ORCID: https://orcid.org/0000-0001-8809-8564)
• Fuqiu Li (ORCID: https://orcid.org/0000-0002-2175-5782)
• Min Zheng (ORCID: https://orcid.org/0000-0003-4565-844X)
• Dong Lv (ORCID: https://orcid.org/0009-0004-4151-8372)
• Jinnan Li (ORCID: https://orcid.org/0000-0002-3290-9687)
• Xuan Wang (ORCID: https://orcid.org/0000-0002-4160-0761)

Institutions

• Nantong University (CN)
• Sichuan University (CN)
• West China Hospital of Sichuan University (CN)
• Yancheng First People's Hospital (CN)
• Zhejiang Provincial People's Hospital (CN)
• Second Affiliated Hospital of Xi'an Jiaotong University (CN)
• First Hospital of China Medical University (CN)
• Second Affiliated Hospital of Jilin University (CN)
• Guangdong Academy of Medical Sciences (CN)
• Lilly (China) (CN)
• Guangdong Provincial People's Hospital (CN)
• Second Affiliated Hospital of Zhejiang University (CN)
• China Medical University (CN)

Publication Details

Journal

Advances in Therapy

Published

2024-11-13

DOI

https://doi.org/10.1007/s12325-024-03030-5

Citations

5

Primary Topic

Psoriasis: Treatment and Pathogenesis

Type

article

Field-Weighted Citation Impact

1.20

Funders

• Eli Lilly and Company